Nursing Elites

1. A client with a prescription for Vasopressin to treat Diabetes Insipidus is being taught by a healthcare professional. Which of the following client statements indicates an understanding of the teaching?

• A. I will reduce my sodium intake.
• B. I should increase my water intake.
• C. I will notify my doctor if I develop chest pain.
• D. I should take this medication with food.

Correct answer: C

Rationale: The correct answer is C because Vasopressin can cause vasoconstriction, potentially leading to chest pain. It is crucial for the client to inform their healthcare provider immediately if they experience chest pain while on Vasopressin therapy to address any potential cardiovascular complications promptly. Choices A, B, and D are incorrect. While maintaining adequate hydration is essential with Vasopressin therapy due to its antidiuretic effect, increasing water intake is not the most critical aspect to monitor. Reducing sodium intake may be beneficial in some cases but is not directly related to the potential side effects of Vasopressin. Taking the medication with food is not a specific instruction for Vasopressin administration.

2. A client has a prescription for Clonidine to treat hypertension. Which of the following instructions should the nurse include?

• A. Discontinue the medication if you experience dry mouth.
• B. Take the medication at the same time each day.
• C. Double the dose if you miss a dose.
• D. Avoid drinking orange juice while taking this medication.

Correct answer: B

Rationale: Correct Answer: Taking Clonidine at the same time each day is crucial to ensure consistent blood levels and effectively manage blood pressure. Consistency in timing helps optimize the medication's effectiveness in controlling hypertension.

3. Why does a nurse on an oncology unit verify a client's current cumulative lifetime dose of doxorubicin before administering it to a client with breast cancer?

• A. Excessive doxorubicin can result in myelosuppression.
• B. Exceeding the lifetime cumulative dose limit of doxorubicin may lead to extravasation.
• C. An excess amount of doxorubicin can lead to cardiomyopathy.
• D. Exceeding the lifetime cumulative dose limit of doxorubicin may cause red-tinged urine and sweat.

Correct answer: C

Rationale: Verifying the client's current cumulative lifetime dose of doxorubicin is necessary because excessive amounts of the medication can lead to cardiomyopathy, a serious and potentially life-threatening side effect. By monitoring the cumulative dose, healthcare providers can help prevent cardiotoxicity and ensure patient safety during treatment.

4. What is the antidote for Heparin?

• A. Protamine sulfate
• B. Vitamin K
• C. Naloxone
• D. Toradol

Correct answer: A

Rationale: The correct answer is A: Protamine sulfate. Heparin is an anticoagulant that prevents blood clotting. Protamine sulfate is the antidote for Heparin as it binds to heparin, neutralizing its anticoagulant effects. Vitamin K is not the antidote for Heparin; it is used to reverse the effects of warfarin, another anticoagulant. Naloxone is an opioid antagonist for opioids, and Toradol is a nonsteroidal anti-inflammatory drug (NSAID) for pain relief. Therefore, the correct antidote for Heparin is Protamine sulfate.

5. A client has a new prescription for Hydralazine. Which of the following side effects should the nurse instruct the client to monitor for and report?

• A. Orthostatic hypotension
• B. Increased heart rate
• C. Dark-colored urine
• D. Persistent cough

Correct answer: B

Rationale: Corrected Rationale: Hydralazine, a vasodilator, can cause reflex tachycardia, leading to an increased heart rate. This side effect should be reported to the healthcare provider to ensure appropriate management and monitoring of the client's condition. Choice A (Orthostatic hypotension) is incorrect as Hydralazine is more likely to cause reflex tachycardia than orthostatic hypotension. Choice C (Dark-colored urine) and Choice D (Persistent cough) are unrelated to the common side effects of Hydralazine and should not be the focus of monitoring for this medication.

Similar Questions